Prevention of HIV-associated respiratory illness in children in developing countries: Potential benefits

International Journal of Tuberculosis and Lung Disease

Volumn 7, Issue 9, 2003, Pages 820-827

  Zar, Heather J ^a  

^a RED CROSS WAR MEMORIAL CHILDREN S HOSPITAL   (South Africa)

Author keywords

Children; HIV; PCP; Prevention; Respiratory; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; BCG VACCINE; CD4 ANTIGEN; COTRIMOXAZOLE; DAPSONE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FANSIDAR; HAEMOPHILUS INFLUENZAE VACCINE; IMMUNOGLOBULIN; INFLUENZA VACCINE; ISONIAZID; MEASLES VACCINE; PENTAMIDINE; PERTUSSIS VACCINE; PLACEBO; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; PYRIMETHAMINE; RETINOL; ZINC;

ANTIBIOTIC RESISTANCE; BACTERIAL PNEUMONIA; BENEFICENCE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LOWEST INCOME GROUP; MALARIA; META ANALYSIS; MILIARY TUBERCULOSIS; MORBIDITY; MORTALITY; NONHUMAN; NUTRITION; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETINOL DEFICIENCY; REVIEW; RISK FACTOR; SIDE EFFECT; STREPTOCOCCUS PNEUMONIAE; SURVIVAL; TREATMENT INDICATION; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CHEMOPREVENTION; CHILD; CHILD WELFARE; DEVELOPING COUNTRIES; HIV INFECTIONS; HUMANS; IMMUNIZATION PROGRAMS; ISONIAZID; MICRONUTRIENTS; NUTRITIONAL STATUS; POVERTY; RESPIRATORY TRACT DISEASES; TUBERCULOSIS, PULMONARY;

EID: 0141493438     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Graham S M, Coulter J B S, Gilks C F. Pulmonary disease in HIV-infected African children. Int J Tuberc Lung Dis 2001; 5: 12-23.
2. Kaplan J E, Masur, H, Holmes, K K, eds. Prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin Infect Dis 1995; 21 (Suppl 1): S1-141.
3. Bucher H C, Griffith L E, Guyatt G H, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999; 13: 501-507.
4. Zar H J, Maartens G, Wood R, Hussey G. Pneumocystis carinii pneumonia (PCP) in HIV infected patients in Africa: an important pathogen? S Afr Med J 2000; 90: 684-688.
5. Carr A, Tindall B, Penny R, Cooper D A. Trimethoprim-sulphamethoxazole appears more effective than aerosolized pentamidine as secondary prophylaxis against Pneumocystis carinii pneumonia in patients with AIDS. AIDS 1992; 6: 165-171.
6. Schneider M M, Hoepelman A I, Eeftinck Schattenkerk J K, et al. A controlled trial of aerosolised pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS treatment group. N Engl J Med 1992; 327: 1836-1841.
7. Podzamer D, Santin M, Jimenez J, Casanova A. Thrice weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocysitis carinii pneumonia in HIV-infected patients. AIDS 1993; 7: 501-506.
8. Graham S M, Mtitimila E I, Kamanga H S, et al. Clinical presentation and outcome of Pneumocystis carinii pneumonia in Malawian children. Lancet 2000; 355: 369-373.
9. Zar H J, Dechaboon A, Hanslo D, et al. Pneumocystis carinii pneumonia in South African children infected with human immunodeficiency virus. Pediatr Infect Dis J 2000; 19: 603-607.
10. Madhi S A, Cutland C, Ismail K, O'Reilly C, Mancha A, Klugman K P. Ineffectiveness of trimethoprim-sulfamethoxazole prophylaxis and the importance of bacterial and viral coinfections in African children with Pneumocystis carinii pneumonia. Clin Infect Dis 2002; 35: 1120-1126.
11. Duong T, Ades A E, Gibb D M, Tookey P A, Masters J. Vertical transmission rates for HIV in the British Isles: estimates based on surveillance data. BMJ 1999; 319: 1227-1229.
12. Chokephaibulkit K, Wanachiwanawain F, Chearskul S, Wanprapa N, Unganot K. Pneumocystis carinii severe pneumonia among human immunodeficiency virus-infected children in Thailand: the effect of primary prophylaxis strategy. Pediatr Infect Dis J 1999; 18: 147-152.
13. Rigaud M, Pollack H, Leibovitz E, et al. Efficacy of primary chemoprophylaxis against Pneumocystis carinii pneumonia during the first year of life in infants infected with human immunodeficiency virus type 1. J Pediatr 1994; 125: 476-480.
14. Thea D M, Lambert G, Weedon J, et al. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early deaths in a cohort of 112 human immunodeficiency virus-infected infants. Pediatrics 1996; 97: 59-64.
15. Wiktor S Z, Sassan-Morokro M, Grant A D, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1 infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999; 353: 1469-1475.
16. Anglaret X, Chene G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1 infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Lancet 1999; 353: 1463-1468.
17. Castebon K, Anglaret X, Attia A, et al. Effect of early chemoprophylaxis with cotrimoxazole on nutritional status evolution in HIV-1 infected adults in Abidjan, Cote d'Ivoire. AIDS 2001; 15: 869-876.
18. Badri M, Ehrlich R, Wood R, Maartens G. Initiating cotrimoxazole prophylaxis in HIV infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. AIDS 2001; 15: 1143-1148.
19. Spector S A, Gelber R D, McGrath N, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. N Engl J Med 1994; 331: 1181-1187.
20. Huebner R, Wasas A, Mushi A, Mazhani L, Klugman K. Nasopharyngeal carriage and antimicrobial resistance in isolates of Streptococcus pneumoniae and Haemophilus influenzae type b in children under 5 years of age in Botswana. Int J Infect Dis 1998; 3: 18-25.
21. Woolfson A, Huebner R, Chola S, Godfrey-Fausset P, Klugman K. Nasopharyngeal carriage of community-acquired, antibiotic-resistant Streptococcus pneumoniae in a Zambian paediatric population. Bull World Health Organ 1997; 75: 453-462.
22. Kazanjian P, Locke A B, Hossler P A, et al. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS 1998; 12: 873-878.
23. Lucas S B, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a West African city. AIDS 1993; 7: 1569-1579.
24. Kamanfu G, Mlika-Cabanne N, Girard P M, et al. Pulmonary complications of human immunodeficiency virus infection in Bujumbura, Burundi. Am Rev Respir Dis 1993; 147: 658-663.
25. Coovadia H M, Jeena P, Wilkinson D. Childhood human immunodeficiency virus and tuberculosis co-infections: reconciling conflicting data. Int J Tuberc Lung Dis 1998; 2: 844-851.
26. Jeena P M, Pillay P, Pillay T, Coovadia H M. Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. Int J Tuberc Lung Dis 2002; 6: 672-678.
27. Rieder H L, Cauthen G M, Comstock G W, Snider D E. Epidemiology of tuberculosis in the United States. Epidemiol Rev 1989; 11: 79-98.
28. WHO Global Tuberculosis Programme/UNAIDS. Preventative therapy against tuberculosis in people living with HIV. Wkly Epidemiol Rec 1999; 74: 385-398.
29. Wilkinson D, Squire S B, Garner P. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. BMJ 1998; 317: 625-629.
30. Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow-up study in Guinea-Bissau, West Africa. BMJ 2000; 321: 1435-1439.
31. Breiman R F, Keller D W, Phelan M A, et al. Evaluation of effectiveness of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-infected patients. Arch Intern Med 2000; 160: 2633-2638.
32. Dworkin M S, Ward J W, Hanson D L, Jones J L, Kaplan J E. Pneumococcal disease among human immunodeficiency virus-infected persons: incidence, risk factors and impact of vaccination. Clin Infect Dis 2001; 32: 794-800.
33. Guerrero M, Kruger S, Saitoh A, et al. Pneumonia in HIV-infected patients: a case-control survey of factors involved in risk and prevention. AIDS 1999; 13: 1971-1975.
34. Fine M J, Smith M A, Carson C A, et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomised controlled trials. Arch Intern Med 1994; 154: 2666-2677.
35. French N, Nakiyingi J, Carpenter L M, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial. Lancet 2000; 355: 2106-2111.
36. World Health Organization position paper. Pneumococcal vaccines. Wkly Epidemiol Rec 1999; 74: 177-183.
37. Kyaw M H, Jones I G, Campbell H. Prevention of pneumococcal disease in children. Pneumococcal conjugate vaccines: their use globally could have a major impact on public health. Acta Paediatr 2001; 90: 473-476.
38. Whitney C G, Farley M M, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003; 348: 1737-1746.
39. King JC, Vink P E, Farley J J, et al. Safety and immunogenicity of three doses of a five-valent pneumococcal conjugate vaccine in children younger than 2 years of age with and without human immunodeficiency virus infection. Paediatrics 1997; 99: 575-580.
40. Madhi S A. Use of bacterial-conjugate vaccines in HIV-1-infected children. Curr Allergy Clin Immunol 2003; 16: 53-59.
41. Heath P T. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data. Pediatr Infect Dis J 1998; 17 (Suppl): S117-S122.
42. Mulholland K, Hilton S, Adegbola R, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997; 349: 1191-1197.
43. Madhi S A, Petersen K, Khoosal M, et al. Reduced effectiveness of Haemophilus influenzae type b conjugate vaccine in children with a high prevalence of human immunodeficiency virus type 1 infection. Pediatr Infect Dis J 2002; 21: 315-321.
44. Colditz G A, Berkey C S, Mosteller F, et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analysis of the published literature. Pediatrics 1995; 96: 29-35.
45. Rodrigues L C, Diwan V K, Wheeler J G. Protective effect of BCG against tuberculous meningitis and military tuberculosis: a meta-analysis. Int J Epidemiol 1993; 22: 1154-1158.
46. Rosenfeldt V, Paerregaard A, Valerius N H. Disseminated infection with Bacillus Calmette-Guerin in a child with advanced HIV disease. Scand J Infect Dis 1997; 29: 526-527.
47. Besnard M, Sauvion S, Offredo C, et al. Bacillus Calmette-Guerin infection after vaccination of human immunodeficiency virus-infected children. Pediatr Infect Dis J 1993; 12: 993-997.
48. Bologna R, Sarkis C, Trinidad P, Casimir L, Lovadina L, Mecicovsky D. Disseminated BCG infection in children with HIV-1 infection. Durban South Africa: XIII International AIDS Congress, July 2000 [Abstract WePpB1308]
49. Lallemant-Lecoeur S, Lallemant M, Cheynier D, et al. Bacillus Calmette-Guerin immunization in infants born to HIV-1 seropositive mothers. AIDS 1991; 5: 195-199.
50. Waddell R D, Lishimpi K, von Reyn C F, et al. Bacteremia due to Mycobacterium tuberculosis or M. bovis, Bacille Calmette-Guerin (BCG) among HIV- positive children and adults in Zambia. AIDS 2001; 15: 55-60.
51. Perry R T, Mmiro F, Ndugwa C, Semba R D. Measles infection in HIV-infected African infants. Ann N Y Acad Sci 2000; 918: 377-380.
52. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. MMWR 1996; 45: 603-606.
53. Palumbo P, Hoyt L, Demasio K, Oleske J, Connor E. Population-based study of measles and measles immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1992; 11: 1008-1014.
54. Dunn D T, Newell M-L, Peckham C S, Van den Eijden S. Routine vaccination and vaccine -preventable infections in children born to human immunodeficiency virus-infected mothers. Acta Paediatr 1998; 87: 458-459.
55. Ryder R W, Oxtoby M J, Mvula M, et al. Safety and immunogenicity of Bacilli Calmette-Guerin, diptheria-tetanus-pertussis and oral polio vaccine in newborn children in Zaire infected with human immunodeficiency virus. J Pediatr 1993; 122: 687-702.
56. de Martino M, Podda A, Galli L, et al. Acellular pertussis vaccine in children with perinatal human immunodeficiency virus-type 1 infection. Vaccine 1997; 15: 1235-1238.
57. Tasker S A, Treanor J J, Paxton W B, Wallace M R. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double blind, placebo-controlled trial. Ann Intern Med 1999; 131: 430-433.
58. Periquet B A, Jammes N M, Lambert W E, et al. Micronutrient levels in HIV-1 infected children. AIDS 1995; 9: 887-893.
59. Hussey G D, Klein M. A randomized controlled trial of vitamin A in children with severe measles. N Engl J Med 1990; 323: 160-164.
60. Dudley L, Hussey G, Huskinssen J, Kessow G. Vitamin A status, other risk factors and acute respiratory tract infection morbidity in children. S Afr Med J 1997; 87: 65-69.
61. Fawzi WW, Mbise R L, Hertzmark E, et al. A randomized trial of vitamin A supplements in relation to mortality among human immunodeficiency virus-infected and uninfected children in Tanzania. Pediatr Infect Dis 1999; 18: 127-133.
62. The Vitamin A and Pneumonia Working Group. Potential interventions for the prevention of childhood pneumonia in developing countries: a meta-analysis of data from field trials to assess the impact of vitamin A supplementation on pneumonia morbidity and mortality. Bull World Health Organ 1995; 73: 609-619.
63. Fawzi W W, Mbise R, Fakati M R, et al. Vitamin A supplements and the severity of pneumonia among children admitted to hospital in Dar es Salaam, Tanzania. Am J Clin Nur 1998; 68: 187-192.
64. Coutsoudis A, Adhikari M, Pillay K, Kuhn L, Coovadia H M. Effect of vitamin A supplementation on morbidity of low-birth-weight neonates. S Afr Med J 2000; 90: 730-736.
65. Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia H M. Randomized trial testing the effect of vitamin A supplementation on pregnancy outcomes and early mother-to-child HIV-1 transmission in Durban, South Africa. South African Vitamin A Study Group. AIDS 1999; 13: 1517-1524.
66. Bhutta Z A, Black R E, Brown K H, et al. Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. J Pediatr 1999; 135: 689-697.
67. Mocchegiani E, Veccia S, Ancarani F, Scalise G, Fabris N. Benefit of oral zinc supplementation as an adjunct to AZT therapy against opportunistic infections in AIDS. Int J Immunopharmacol 1995; 17: 719-727.
68. Tang A, Graham N, Saah A. Effects of micronutrient intake on survival in HIV-1 infection. Am J Epidemiol 1996; 142: 1244-1256.